#USA #New York #Class Action #Semler Scientific #Pomerantz Law

Class Action Lawsuit Filed Against Semler Scientific

Recent news from Pomerantz LLP has raised concerns among investors of Semler Scientific, Inc. (NASDAQ: SMLR) due to a class action lawsuit that has been brought against the company. This alert serves as a reminder for those who have incurred losses on their investments in Semler Scientific to take note of the upcoming deadlines associated with this lawsuit.

Understanding the Class Action Suit

The class action suit pertains to allegations that Semler and certain officers or directors may have engaged in securities fraud or other unlawful business practices. This is particularly concerning for investors who acquired Semler's securities during the Class Period specified in the lawsuit. If you fall into this category, you have until October 28, 2025, to request the Court to appoint you as Lead Plaintiff. Guidance on how to proceed can be obtained through Pomerantz LLP by contacting Danielle Peyton at the firm.

Background and Impact of Allegations

The lawsuit follows troubling disclosures made by Semler in its annual report for the full fiscal year of 2024. The company indicated possible legal challenges, stating there was a risk that the U.S. Department of Justice may file complaints related to the testing of their medical devices. This raised alarm as Semler had previously received a civil investigative demand from the DOJ back in 2017 concerning their QuantaFlo device, which tests for peripheral artery disease.

In addition to these revelations, Semler reported failed settlement discussions with the DOJ in February 2025, which had an immediate negative impact on its stock price. Following efforts to negotiate an agreement, Semler's shares dropped significantly upon the announcement of a $29.75 million settlement agreement with the DOJ.

Market Reactions

The implications of these developments have not gone unnoticed in the market. In March 2025, immediately following rumors about the DOJ's stance and the announcement regarding settlement discussions, Semler's stock price experienced a steep decline. This highlights the immediate ramifications on investor confidence and the financial standing of the company as a whole.

Furthermore, the announcement in April of a preliminary agreement with the DOJ to settle claims did not assuage market concerns, as shares fell once again the following trading day. These repeated downturns demonstrate the volatility encapsulated within the stock following news of legal and regulatory scrutiny, indicating critical ongoing challenges for the company.

The Role of Pomerantz LLP

Pomerantz LLP, renowned for its expertise in corporate, securities, and antitrust class litigation, provides representation and support for investors impacted by these events. Founded by the influential Abraham L. Pomerantz, the firm is dedicated to promoting the rights of victims affected by securities fraud and corporate malfeasance. Having secured significant damages in many cases, they are positioned to guide affected investors through this complicated litigation landscape.

Next Steps for Investors

Investors who have incurred losses on their investments in Semler Scientific are encouraged to reach out promptly to learn more about their rights and the next steps. The upcoming deadlines are crucial, and the opportunity to participate in the action may lead to potential recoveries. Details about the complaint and joining the class action can be found on Pomerantz's official website.

In conclusion, the class action lawsuit against Semler Scientific is a pivotal moment for investors, and those affected must act swiftly to safeguard their interests in light of this legal challenge. Pomerantz LLP stands ready to assist impacted stakeholders in navigating these turbulent times within the financial markets.